Efficacy and Safety of Edoxaban in Patients With AF and HF

Slides:

Advertisements

Similar presentations

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Advertisements

ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Covering the Bases in Cardioversion

Silent No More:.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

NOACs for Cancer-Associated Thrombosis:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

The ABCs of AF.

NOACs in Clinical Practice: Are They All the Same?

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Unmet Needs in the Secondary Prevention in ACS

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Up to Date on Which NOAC for Which Patient

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Through Thick and Thin.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

VTE Treatment Conventional Approach

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

Tackling CV Risk in T2DM.

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Dos and Don’ts for High-Risk Elderly Patients With AF

Atrial Fibrillation.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Anticoagulation and Thrombosis Management

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Identifying High-Risk AF Patients

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

CAD and HF Often Coexist

A Case Challenge.

New European Anticoagulant Approvals Will They Affect Practical Guidance?

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Antithrombotic Therapy in Vascular Protection: From CAD to HF

Updates in Anticoagulation: Key Sessions at ESC 2017

NOAC Studies in VTE AF Studies Superior Outcomes.

Elevated Admission Plasma Glucose Following ACS

DECLARE-TIMI 58.

The ABCs of AF.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

What is “AF Burden”?. What is “AF Burden”? AF Burden and Stroke Risk ASSERT Study.

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

Translating Data From Trial to Practice

Presentation transcript:

Efficacy and Safety of Edoxaban in Patients With AF and HF

HF in ENGAGE AF-TIMI 48 Select Baseline Characteristics

Efficacy and Safety Outcomes by HF Class

Efficacy and Safety Outcomes by Treatment

Conclusions

Patients With Prior Cerebrovascular Event

ENGAGE AF-TIMI 48 Efficacy and Safety

Edoxaban vs VKA in Patients With Previous Cerebrovascular Events

Assessing Risk CHA2DS2-VASc

Absolute Risk in Patients With Previous Cerebrovascular Events

Conclusions

Sudden Cardiac Death in AF

Causes of Death in ENGAGE AF-TIMI 48

Characterization of SCD Events

Predictors of SCD in ENGAGE AF

Conclusions

Impact of Renal Function in ENGAGE AF-TIMI 48

Edoxaban Renal Implications in ENGAGE AF-TIMI 48

Outcomes in ENGAGE AF-TIMI 48 Based on CrCl

Edoxaban Concentrations Based on Renal Clearance

Conclusions

Impact of NOACs in Treating AF: Insights From ENGAGE AF-TIMI 48

Percentage of Strokes Attributable to AF Increases With Age

AF and Stroke Summary of Randomized Studies

NOAC 4-Trial Meta-Analysis Prespecified Meta-Analysis of All 71,683 Patients

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)